-
Sanofi announces acquisition of Inhibrx, which will be included in INBRX-101 assets
On January 23rd, Sanofi announced on its official website that it had reached a final agreement with biopharmaceutical listed company Inhibrx. According to the agreement, Sanofi agreed to acquire Inh ... -
Sanofi: New indications for dabitol have been given priority review by the US FDA
On February 23rd, Sanofi announced that the US Food and Drug Administration (FDA) had granted dabitol& Reg; Priority review of the application for market authorization (sBLA) for the sixth potential ...- stevenbaul
- 2024-2-23
- サポート
- に反対
- 返信
- コレクション
-
Sanofi continues to deeply cultivate the Chinese market
This year marks the 60th anniversary of the establishment of diplomatic relations between China and France. As one of the first French medical and health enterprises to take root in China, Sanofi wil ... -
Sanofi announces the official commercialization and listing of Leweichu in China
Sanofi announces the official commercialization and listing of Leweichu in China. Today, it was learned from Sanofi that the company's long-acting monoclonal antibody Leweichu (Nisevirumab Injection) ... -
Sanofi's BTK inhibitor is declared for market in China
New Beijing News (Reporter Zhang Zhaohui) On December 30th, the official website of the Drug Evaluation Center of the National Medical Products Administration announced that the application for the l ...